In Situ-Forming Oleogel Implant for Rivastigmine Delivery

@article{Vintiloiu2007InSO,
  title={In Situ-Forming Oleogel Implant for Rivastigmine Delivery},
  author={Anda Vintiloiu and Michel Lafleur and Guillaume Bastiat and Jean-Christophe Leroux},
  journal={Pharmaceutical Research},
  year={2007},
  volume={25},
  pages={845-852}
}
To provide a simplified dosing schedule and potentially reduce side effects associated to peak plasma concentrations, an in situ-forming oleogel implant was studied for the sustained-release of rivastigmine. The gel was prepared by dissolving 5–10% (w/w) N-stearoyl l-alanine methyl ester (SAM) organogelator in safflower oil containing either dissolved rivastigmine or its dispersed hydrogen tartrate salt. Rheological analysis, differential scanning calorimetry, and infrared spectroscopy were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

A meta-analysis Can

  • K. L. Lanctôt, N. Herrmann, +5 authors safety of choliesterase inhibitors in Alzheimers disease
  • Med. Assoc. J. 169:557–564
  • 2003
Highly Influential
7 Excerpts

progress or profit? Nat

  • C. Mount, C. Downton. Alzheimer disease
  • Med. 12:780–784
  • 2006
1 Excerpt

Efficacy and safety of choliesterase inhibitors in Alzheimer _ s disease : A meta - analysis Can

  • N. Herrmann, K. K. Yau, L. R. Khan, B. A. Liu, M. M. Loulou, T. R. Einarson
  • Med . Assoc . J .
  • 2005

Similar Papers

Loading similar papers…